Clarus Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2003-01-01
- Employees
- 11
- Market Cap
- -
Pharmacokinetic Study of Oral Testosterone (T) Ester Formulations in Hypogonadal Men
Phase 2
Completed
- Conditions
- Hypogonadism
- Interventions
- Drug: Oral testosterone undecanoate (TU) (300 mg T equivalents/dose)Drug: Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (400 mg T equivalents/dose)Drug: Oral testosterone undecanoate (TU) (200 mg T equivalents/dose with and without food)Drug: Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (300 mg T equivalents/dose)
- First Posted Date
- 2008-06-11
- Last Posted Date
- 2021-06-25
- Lead Sponsor
- Clarus Therapeutics, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT00695110
- Locations
- 🇺🇸
Alabama Internal Medicine, Birmingham, Alabama, United States
🇺🇸Alabama Clinical Therapeutics, Birmingham, Alabama, United States
🇺🇸dgd Research, Inc., San Antonio, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath